Skip to main content
Premium Trial:

Request an Annual Quote

Bill Gates Pours Money into Computational Drug Design

Bill Gates has invested $10 million in computational drug design company Schrödinger, Derek Lowe reports in a Nature News column. The company, which is privately owned, doesn't publicly release financial information, but Lowe says its yearly revenue is somewhere around $20 million, making Gates' contribution "substantial." Lowe says Schrödinger will most likely use the money for long-term projects, like collaborative efforts wherein industrial drug-discovery organizations test the company's products in the real world and send the results back to the programmers so they can make improvements.

Deepak Singh at Business Bytes Genes Molecules says that's a possibility, but that there is an opportunity with this investment to "take the productization of science one step further." One of the challenges of computational drug design is pushing the technology further while conducting a solid project, Singh says. With this money, Schrödinger can afford to take some risks in cutting-edge science. "I have a good feeling about this and the future of not just the company, but what impact this might have on the craft of molecular modeling and computational drug discovery over the next decade," he adds.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.